

## Monitoring medicines

[Consultez la version française](#) ■ ■

ANSM receives or detects potential signals from various sources (pharmacovigilance, medication error and misuse reports, articles from monitoring the scientific literature, pharmacovigilance surveys conducted by CRPV, etc.). We categorise each signal according to its level of risk and analyse it by cross-referencing the data at our disposal in order to confirm or refute it. Discussions are held with the Regional Pharmacovigilance Centre (CRPV) network, but also with patient representatives and healthcare professionals throughout the signal evaluation process.

- + [Signal identification and processing](#)
- + [Managing medication errors](#)

In addition, we establish an enhanced surveillance programme based on a preliminary risk analysis of certain situations or products, without there necessarily being an identified signal. Various tools are used to perform this enhanced surveillance: pharmacovigilance surveys, statistical signal detection, monitoring of surveillance databases, etc.

- + [Enhanced surveillance of medicines](#)

This continuous surveillance enables ANSM to implement new or supplementary measures, if necessary, in addition to those already in place.

- + [Risk-reduction measures](#)

Finally, ANSM oversees medicine advertisements before they are published.

- + [Control over medicine advertising](#)